pronethalol

Also known as nethalide, Alderlin, pronetalol

Pronethalol (also known as nethalide or compound 38,174; trade name Alderlin) was an early non-selective beta blocker clinical candidate. It was the first beta blocker to be developed by James Black and associates at Imperial Chemical Industries, and the first to enter clinical use, in November 1963.

In the Vinony graph

Vinony's link graph records 1,564 inbound references to pronethalol, and connects out to propranolol, levonordefrin and 2C-G.

It is catalogued under topics including 2-Naphthyl compounds, Beta blockers and Chemical pages without DrugBank identifier.

Vinony links it to 8 Wikipedia language editions.

Chemical data

Formula: C15H19NO
Molecular weight: 229.32 g/mol
IUPAC name: 1-naphthalen-2-yl-2-(propan-2-ylamino)ethanol
SMILES: CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O
InChIKey: HRSANNODOVBCST-UHFFFAOYSA-N
XLogP: 3
Polar surface area: 32.3 Å²
H-bond donors: 2
H-bond acceptors: 2
Formal charge: 0

via PubChem

Drug data · ChEMBL

Withdrawn

Max clinical phase: Approved
Molecule type: Small molecule

via ChEMBL · EBI

Wikidata facts

Subclass of: chemical compound
Mass: 229.147

Show 2 more facts

chemical formula: C₁₅H₁₉NO
canonical SMILES: CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O

Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

2 sections

Contents

See also
References

However, it was never used widely due to carcinogenicity in mice, which was thought to result from formation of a carcinogenic naphthalene epoxide metabolite, and was superseded by propranolol from 1965 onward.

Excerpted from Wikipedia’s “pronethalol” article, available under the CC BY-SA 4.0 licence.